Defective VLDL metabolism and severe atherosclerosis in mice expressing human apolipoprotein E isoforms but lacking the LDL receptor

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1684, Issue 1-3, 2004, Pages 8-17

  Knouff, Christopher ^a   Briand, Olivier ^b   Lestavel, Sophie ^b   Clavey, Veronique ^b   Altenburg, Michael ^a   Maeda, Nobuyo ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Animal model; Atherosclerosis; HSPG; LDL; LDL receptor; LDLR; low density lipoprotein; low density lipoprotein receptor; low density lipoprotein receptor related protein; LRP; Plasma cholesterol; Type III hyperlipoproteinemia; very low density lipoprotein; VLDL

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; ISOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; BINDING AFFINITY; CHOLESTEROL METABOLISM; CONTROLLED STUDY; DISEASE SEVERITY; HUMAN; HYPERLIPIDEMIA; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANIMALS; AORTA; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; CELLS, CULTURED; CHOLESTEROL, VLDL; DIET; FIBROBLASTS; GENOTYPE; HUMANS; LIPIDS; LIPOPROTEINS; MALE; MICE; MICE, KNOCKOUT; PROTEIN BINDING; PROTEIN ISOFORMS; RECEPTORS, LDL;

ANIMALIA;

EID: 4344691010     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbalip.2004.03.004     Document Type: Article

References (39)

1. Brown M.S., Goldstein J.L. A receptor-mediated pathway for cholesterol homeostasis. Science. 232:1986;34-47
2. Willnow T.E. Mechanisms of hepatic chylomicron remnant clearance. Diabet. Med. 14(Suppl. 3):1997;S75-S80
3. Mahley R.W., Ji Z.S. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J. Lipid Res. 40:1999;1-16
4. Strickland D.K., Gonias S.L., Argraves W.S. Diverse roles for the LDL receptor family. Trends Endocrinol. Metab. 13:2002;66-74
5. Hussain M.M. Structural, biochemical and signaling properties of the low-density lipoprotein receptor gene family. Front. Biosci. 6:2001;D417-D428
6. Mahley R.W. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 240:1988;622-630
7. Weisgraber K.H., Rall S.C. Jr., Mahley R.W., Milne R.W., Marcel Y.L., Sparrow J.T. Human apolipoprotein E. Determination of the heparin binding sites of apolipoprotein E3. J. Biol. Chem. 261:1986;2068-2076
8. Saxena U., Ferguson E., Bisgaier C.L. Apolipoprotein E modulates low density lipoprotein retention by lipoprotein lipase anchored to the subendothelial matrix. J. Biol. Chem. 268:1993;14812-14819
9. Thuren T., Weisgraber K.H., Sisson P., Waite M. Role of apolipoprotein E in hepatic lipase catalyzed hydrolysis of phospholipid in high-density lipoproteins. Biochemistry. 31:1992;2332-2338
10. Davignon J., Cohn J.S., Mabile L., Bernier L. Apolipoprotein E and atherosclerosis: insight from animal and human studies. Clin. Chim. Acta. 286:1999;115-143
11. Boerwinkle E., Utermann G. Simultaneous effects of the apolipoprotein E polymorphism on apolipoprotein E, apolipoprotein B, and cholesterol metabolism. Am. J. Hum. Genet. 42:1988;104-112
12. Wilson P.W., Schaefer E.J., Larson M.G., Ordovas J.M. Apolipoprotein E alleles and risk of coronary disease. A meta-analysis. Arterioscler. Thromb. Vasc. Biol. 16:1996;1250-1255
13. Brewer H.B. Jr., Zech L.A., Gregg R.E., Schwartz D., Schaefer E.J. NIH conference. Type III hyperlipoproteinemia: diagnosis, molecular defects, pathology, and treatment. Ann. Intern. Med. 98:1983;623-640
14. Davignon J., Gregg R.E., Sing C.F. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis. 8:1988;1-21
15. Weisgraber K.H., Innerarity T.L., Mahley R.W. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J. Biol. Chem. 257:1982;2518-2521
16. Sullivan P.M., Mezdour H., Aratani Y., et al. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J. Biol. Chem. 272:1997;17972-17980
17. Sullivan P.M., Mezdour H., Quarfordt S.H., Maeda N. Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2. J. Clin. Invest. 102:1998;130-135
18. Knouff C., Hinsdale M.E., Mezdour H., et al. Apo E structure determines VLDL clearance and atherosclerosis risk in mice. J. Clin. Invest. 103:1999;1579-1586
19. Ishibashi S., Brown M.S., Goldstein J.L., Gerard R.D., Hammer R.E., Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. [see comments] J. Clin. Invest. 92:1993;883-893
20. Leroy A., Vu-dac N., Koffigan M., Clavey V., Fruchart J.C. Characterization of a monoclonal antibody that binds to apolipoprotein E and to lipoprotein of human plasma containing apo E. Applications to ELISA quantification of plasma apo E. J. Immunoass. 9:1988;309-334
21. Peterson G.L. A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal. Biochem. 83:1977;346-356
22. Clavey V., Lestavel-Delattre S., Copin C., Bard J.M., Fruchart J.C. Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E. Arterioscler. Thromb. Vasc. Biol. 15:1995;963-971
23. Bilheimer D.W., Eisenberg S., Levy R.I. The metabolism of very low density lipoprotein proteins. I. Preliminary in vitro and in vivo observations. Biochim. Biophys. Acta. 260:1972;212-221
24. Zhang S.H., Reddick R.L., Burkey B., Maeda N. Diet-induced atherosclerosis in mice heterozygous and homozygous for apolipoprotein E gene disruption. J. Clin. Invest. 94:1994;937-945
25. Bohnet K., Pillot T., Visvikis S., Sabolovic N., Siest G. Apolipoprotein (apo) E genotype and apoE concentration determine binding of normal very low density lipoproteins to HepG2 cell surface receptors. J. Lipid Res. 37:1996;1316-1324
26. Knouff C., Malloy S., Wilder J., Altenburg M.K., Maeda N. Doubling expression of the low density lipoprotein receptor by truncation of the 3′-untranslated region sequence ameliorates type iii hyperlipoproteinemia in mice expressing the human apoe2 isoform. J. Biol. Chem. 276:2001;3856-3862
27. van Dijk K.W., van Vlijmen B.J., van der Zee A., et al. Reversal of hypercholesterolemia in apolipoprotein E2 and apolipoprotein E3-Leiden transgenic mice by adenovirus-mediated gene transfer of the VLDL receptor. Arterioscler. Thromb. Vasc. Biol. 18:1998;7-12
28. Kita T., Goldstein J.L., Brown M.S., Watanabe Y., Hornick C.A., Havel R.J. Hepatic uptake of chylomicron remnants in WHHL rabbits: a mechanism genetically distinct from the low density lipoprotein receptor. Proc. Natl. Acad. Sci. U. S. A. 79:1982;3623-3627
29. Rajavashisth T.B., Kaptein J.S., Reue K.L., Lusis A.J. Evolution of apolipoprotein E: mouse sequence and evidence for an 11- nucleotide ancestral unit. Proc. Natl. Acad. Sci. U. S. A. 82:1985;8085-8089
30. Luo C.C., Li W.H., Chan L. Structure and expression of dog apolipoprotein A-I, E, and C-I mRNAs: implications for the evolution and functional constraints of apolipoprotein structure. J. Lipid Res. 30:1989;1735-1746
31. Weisgraber K.H. Apolipoprotein E: structure-function relationships. Adv. Protein Chem. 45:1994;249-302
32. Braddock D.T., Mercurius K.O., Subramanian R.M., Dominguez S.R., Davies P.F., Meredith S.C. Conformationally specific enhancement of receptor-mediated LDL binding and internalization by peptide models of a conserved anionic N-terminal domain of human apolipoprotein E. Biochemistry. 35:1996;13975-13984
33. Rohlmann A., Gotthardt M., Hammer R.E., Herz J. Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. J. Clin. Invest. 101:1998;689-695
34. Kim D.H., Inagaki Y., Suzuki T., et al. A new low density lipoprotein receptor related protein, LRP5, is expressed in hepatocytes and adrenal cortex, and recognizes apolipoprotein E. J. Biochem. (Tokyo). 124:1998;1072-1076
35. van Vlijmen B.J., Rohlmann A., Page S.T., et al. An extrahepatic receptor-associated protein-sensitive mechanism is involved in the metabolism of triglyceride-rich lipoproteins. J. Biol. Chem. 274:1999;35219-35226
36. Huang Y., Liu X.Q., Rall S.C. Jr., Mahley R.W. Apolipoprotein E2 reduces the low density lipoprotein level in transgenic mice by impairing lipoprotein lipase-mediated lipolysis of triglyceride-rich lipoproteins. J. Biol. Chem. 273:1998;17483-17490
37. Huang Y., Liu X.Q., Rall S.C. Jr., et al. Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia. J. Biol. Chem. 273:1998;26388-26393
38. Huang Y., Ji Z.S., Brecht W.J., Rall S.C. Jr., Taylor J.M., Mahley R.W. Overexpression of apolipoprotein E3 in transgenic rabbits causes combined hyperlipidemia by stimulating hepatic VLDL production and impairing VLDL lipolysis. Arterioscler. Thromb. Vasc. Biol. 19:1999;2952-2959
39. Rudling M. Hepatic mRNA levels for the LDL receptor and HMG-CoA reductase show coordinate regulation in vivo. J. Lipid Res. 33:1992;493-501